RE:RE:RE:RE:RE:RE:RE:RE:ONCY's Bracelet-1 was in HR+/HER2 negative breast cancerQuentin30 while IND-213 as a study wasn't powered for statistical significance, because of the low number pf patients enrolled, the trial's results were statistically evaluated showing a statistically significant overall survival improvement and clinical benefit in the treatment arm with pelareorep (montherapy) + paclitaxel vs paclitaxel (alone) .